Triple combination therapy may be optimal for CV protection in type 2 diabetes

Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.The impact of triple therapy on CV outcomes remains difficult to discern; there are no randomized controlled trial data on combination therapy assessing outcomes, Ralph A.

Read the full article here

Related Articles